4 false false false false false false false false false true false false false false false false No description of principal activity 2024-04-01 Sage Accounts Production Advanced 2023 - FRS102_2023 382,481 329,583 xbrli:pure xbrli:shares iso4217:GBP 9430207 2024-04-01 2025-03-31 9430207 2025-03-31 9430207 2024-03-31 9430207 2023-04-01 2024-03-31 9430207 2024-03-31 9430207 2023-03-31 9430207 bus:RegisteredOffice 2024-04-01 2025-03-31 9430207 bus:Director1 2024-04-01 2025-03-31 9430207 bus:Director2 2024-04-01 2025-03-31 9430207 bus:CompanySecretary1 2024-04-01 2025-03-31 9430207 core:WithinOneYear 2025-03-31 9430207 core:WithinOneYear 2024-03-31 9430207 core:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 9430207 core:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 9430207 core:RetainedEarningsAccumulatedLosses 2024-03-31 9430207 core:RetainedEarningsAccumulatedLosses 2023-03-31 9430207 core:RetainedEarningsAccumulatedLosses 2025-03-31 9430207 core:RetainedEarningsAccumulatedLosses 2024-03-31 9430207 core:ShareCapital 2025-03-31 9430207 core:ShareCapital 2024-03-31 9430207 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 9430207 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-03-31 9430207 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 9430207 core:Non-currentFinancialInstruments 2025-03-31 9430207 core:Non-currentFinancialInstruments 2024-03-31 9430207 bus:SmallEntities 2024-04-01 2025-03-31 9430207 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 9430207 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 9430207 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 9430207 bus:AbridgedAccounts 2024-04-01 2025-03-31
COMPANY REGISTRATION NUMBER: 9430207
SKV Medical Limited
Unaudited Abridged Financial Statements
31 March 2025
SKV Medical Limited
Abridged Financial Statements
Year ended 31 March 2025
Contents
Page
Directors' report
1
Abridged statement of income and retained earnings
2
Abridged statement of financial position
3
Notes to the abridged financial statements
5
SKV Medical Limited
Directors' Report
Year ended 31 March 2025
The directors present their report and the unaudited abridged financial statements of the company for the year ended 31 March 2025 .
Directors
The directors who served the company during the year were as follows:
Dr S Bansal
Dr A Agarwal
Small company provisions
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on 1 August 2025 and signed on behalf of the board by:
Dr S Bansal
Dr S Bansal
Director
Company Secretary
Registered office:
90 Copse Hill
Harlow
Essex
CM19 4PP
SKV Medical Limited
Abridged Statement of Income and Retained Earnings
Year ended 31 March 2025
2025
2024
Note
£
£
Gross profit
336,622
317,790
Administrative expenses
26,242
29,838
---------
---------
Operating profit
310,380
287,952
Income from other fixed asset investments
182,621
154,674
Other interest receivable and similar income
22,476
2,141
---------
---------
Profit before taxation
5
515,477
444,767
Tax on profit
132,996
115,184
---------
---------
Profit for the financial year and total comprehensive income
382,481
329,583
---------
---------
Dividends paid and payable
( 1,000)
( 2,000)
Retained earnings at the start of the year
3,574,681
3,247,098
------------
------------
Retained earnings at the end of the year
3,956,162
3,574,681
------------
------------
All the activities of the company are from continuing operations.
SKV Medical Limited
Abridged Statement of Financial Position
31 March 2025
2025
2024
Note
£
£
£
Fixed assets
Tangible assets
6
16,507
33,014
Investments
7
4,366,760
3,595,400
------------
------------
4,383,267
3,628,414
Current assets
Debtors
7,872
Cash at bank and in hand
251,662
206,961
---------
---------
259,534
206,961
Creditors: amounts falling due within one year
686,439
260,494
---------
---------
Net current liabilities
426,905
53,533
------------
------------
Total assets less current liabilities
3,956,362
3,574,881
------------
------------
Net assets
3,956,362
3,574,881
------------
------------
Capital and reserves
Called up share capital
200
200
Profit and loss account
3,956,162
3,574,681
------------
------------
Shareholders funds
3,956,362
3,574,881
------------
------------
These abridged financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its abridged financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of abridged financial statements .
All of the members have consented to the preparation of the abridged statement of income and retained earnings and the abridged statement of financial position for the year ending 31 March 2025 in accordance with Section 444(2A) of the Companies Act 2006.
SKV Medical Limited
Abridged Statement of Financial Position (continued)
31 March 2025
These abridged financial statements were approved by the board of directors and authorised for issue on 1 August 2025 , and are signed on behalf of the board by:
Dr S Bansal
Director
Company registration number: 9430207
SKV Medical Limited
Notes to the Abridged Financial Statements
Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 90 Copse Hill, Harlow, CM19 4PP, Essex.
2. Statement of compliance
These abridged financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The abridged financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The abridged financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 4 (2024: 4 ).
5. Profit before taxation
Profit before taxation is stated after charging:
2025
2024
£
£
Depreciation of tangible assets
16,507
16,508
--------
--------
6. Tangible assets
£
Cost
At 1 April 2024 and 31 March 2025
66,029
--------
Depreciation
At 1 April 2024
33,015
Charge for the year
16,507
--------
At 31 March 2025
49,522
--------
Carrying amount
At 31 March 2025
16,507
--------
At 31 March 2024
33,014
--------
7. Investments
£
Cost
At 1 April 2024
3,595,400
Additions
771,360
------------
At 31 March 2025
4,366,760
------------
Impairment
At 1 April 2024 and 31 March 2025
------------
Carrying amount
At 31 March 2025
4,366,760
------------
At 31 March 2024
3,595,400
------------
8. Related party transactions
There are no transactions with related parties that are required to be disclosed under Financial Reporting Standard for Smaller Entities.